Systemic mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 2, 2012, Pages 294-296

  Jordan, Nicole ^a   Waghmare, Alpana ^a   Abi Ghanem, Alain S ^a   Moon, Aeri ^b   Salvatore, Christine M ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZITHROMYCIN; C REACTIVE PROTEIN; CLARITHROMYCIN; ETHAMBUTOL; INFLIXIMAB; MERCAPTOPURINE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC THERAPY; APPETITE; ARTHRALGIA; ARTHROPATHY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CASE REPORT; CERVICAL LYMPH NODE; CHILD; CHRONIC GASTRITIS; CLINICAL FEATURE; COLITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE CLASSIFICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENITIS; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; GROWTH DISORDER; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; RECURRENT FEVER; REMISSION; SCHOOL CHILD; SIDE EFFECT; SIGMOID; STOMACH EROSION; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CROHN DISEASE; FEMALE; HUMANS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

MYCOBACTERIUM AVIUM COMPLEX;

EID: 84856236620     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31822938c3     Document Type: Article

References (13)

1. Cimzia [package insert]. Smyrna, GA: UCB; 2009.
2. Humira [package insert]. North Chicago, IL: Abbott Laboratories; 2009.
3. Remicade [package insert]. Malvern, PA: Centocor Ortho Biotech; 2009.
4. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009;15:1556-61.
5. Ledingham J,Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford) 2005;44:1205-6. (Pubitemid 41487949)
6. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21.
7. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
8. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13. (Pubitemid 38447195)
9. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
10. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferongamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799-806.
11. Mazurek M, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59:1-25.
12. Sauzullo I, Mengoni F, Scrivo R, et al. Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment. Int J Tuberc Lung Dis 2010;14:834-40.
13. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.